SCHEMBL30946188

SCHEMBL30946188

Cc1cc2cc(CNC(=O)C3(C)CC3)[nH]c2cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MAPT P10636 6/20 0.36
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KDM4E B2RXH2 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ HPGD P15428 3/20 0.33
▸ HSD17B10 Q99714 3/20 0.33
▸ HTT P42858 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ METTL3 Q86U44 4/20 0.33
▸ METTL14 Q9HCE5 4/20 0.33
▸ RET P07949 1/20 0.32
▸ PABPC1 P11940 1/20 0.32
▸ TSHR P16473 2/20 0.32
▸ IKBKB O14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27247917 0.88 SMN1; SMN2 (0.38) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL30920545 0.87 RAB9A (0.42) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27247781 0.86 RAB9A (0.40) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27246821 0.86 RAB9A (0.36) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL30920251 0.85 SMN1; SMN2 (0.38) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27247646 0.85 SMN1; SMN2 (0.38) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27246922 0.85 MTNR1A (0.42) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27383362 0.83 RAB9A (0.38) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL30920782 0.82 SMN1; SMN2 (0.40) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL27246773 0.82 SMN1; SMN2 (0.40) RAB9ANPC1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 RAB9A 105/4885NPC1 102/4885SMN1; SMN2 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback